Added benefit for Janssen's Zytiga for some patients, says German HTA body
This article was originally published in Scrip
Janssen-Cilag's Zytiga (abiraterone acetate) offers considerable added benefit for metastatic prostate cancer patients not eligible for further treatment with docetaxel (Sanofi's Taxotere), says IQWiG, the institute for Germany's Institute for Quality and Efficiency in Healthcare. The institute also concluded that there was no proven added benefit for patients who could still be treated with docetaxel.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.